Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

Clinical Endocrinology

Volumn 81, Issue 4, 2014, Pages 523-528

  Kahal, Hassan ^a   Abouda, G ^b   Rigby, A S ^a   Coady, A M ^b   Kilpatrick, E S ^b   Atkin, S L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ISOPROSTANE DERIVATIVE; LIRAGLUTIDE; PROCOLLAGEN TYPE III AMINO TERMINAL PEPTIDE; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; BODY WEIGHT; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; NAUSEA AND VOMITING; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; LIVER CIRRHOSIS; METABOLISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POLYCYSTIC OVARY SYNDROME; TRIGLYCERIDES;

EID: 84908097545     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12369     Document Type: Article

References (35)

1. Fauser, B.C., Tarlatzis, B.C., Rebar, R.W. et al. (2012) Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility, 97, 28-38.e25.
2. Glueck, C.J., Dharashivkar, S., Wang, P. et al. (2005) Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 122, 206-212.
3. Setji, T.L., Holland, N.D., Sanders, L.L. et al. (2006) Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 91, 1741-1747.
4. Marchesini, G., Moscatiello, S., Di Domizio, S. et al. (2008) Obesity-associated liver disease. Journal of Clinical Endocrinology and Metabolism, 93(11 Suppl 1), S74-S80.
5. Poonawala, A., Nair, S.P. & Thuluvath, P.J. (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology, 32(4 Pt 1), 689-692.
6. Caldwell, S.H., Crespo, D.M., Kang, H.S. et al. (2004) Obesity and hepatocellular carcinoma. Gastroenterology, 127(5 Suppl 1), S97-S103.
7. Angulo, P. (2007) Obesity and nonalcoholic fatty liver disease. Nutrition Reviews, 65(6 Pt 2), S57-S63.
8. Matteoni, C.A., Younossi, Z.M., Gramlich, T. et al. (1999) Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116, 1413-1419.
9. Targher, G. & Byrne, C.D. (2013) Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism, 98, 483-495.
10. Ueno, T., Sugawara, H., Sujaku, K. et al. (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Journal of Hepatology, 27, 103-107.
11. Dixon, J.B., Bhathal, P.S., Hughes, N.R. et al. (2004) Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology, 39, 1647-1654.
12. Cheong, J.Y., Um, S.H., Seo, Y.S. et al. (2012) A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis. Hepato-Gastroenterology, 59, 2592-2597.
13. Tanwar, S., Trembling, P.M., Guha, I.N. et al. (2013) Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology, 57, 103-111.
14. Niemela, O., Risteli, J., Blake, J.E. et al. (1990) Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology, 98, 1612-1619.
15. Gangale, M.F., Miele, L., Lanzone, A. et al. (2011) Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clinical Endocrinology, 75, 520-527.
16. Nauck, M.A., El-Ouaghlidi, A., Hompesch, M. et al. (2003) No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes. Diabetes, 52(Suppl 1), A128.
17. Astrup, A., Rossner, S., Van Gaal, L. et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet, 374, 1606-1616.
18. Mells, J.E., Fu, P.P., Sharma, S. et al. (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. American Journal of Physiology. Gastrointestinal and Liver Physiology, 302, G225-G235.
19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19, 41-47.
20. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome [article online], 2006. Available from http://www.idf.org/webdata/docs/IDF-Meta-def-final.pdf. Accessed on 08/01/2013.
21. Kahal, H., Aburima, A., Ungvari, T. et al. (2013) Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clinical Endocrinology, 79, 252-258.
22. Harrison, S.A., Oliver, D., Arnold, H.L. et al. (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut, 57, 1441-1447.
23. Angulo, P., Hui, J.M., Marchesini, G. et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45, 846-854.
24. Levine, M. & Ensom, M.H. (2001) Post hoc power analysis: an idea whose time has passed? Pharmacotherapy, 21, 405-409.
25. Molenberghs, G. (2007) Editorial: what to do with missing data? Journal of the Royal Statistical Society Series A, 170, 861-863.
26. Engels, J.M. & Diehr, P. (2003) Imputation of missing longitudinal data: a comparison of methods. Journal of Clinical Epidemiology, 56, 968-976.
27. Thoma, C., Day, C.P. & Trenell, M.I. (2012) Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. Journal of Hepatology, 56, 255-266.
28. Cuthbertson, D.J., Irwin, A., Gardner, C.J. et al. (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE, 7, e50117.
29. Preiss, D., Sattar, N., Harborne, L. et al. (2008) The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice, 62, 1337-1343.
30. Rasmussen, M.H., Jensen, L.T., Andersen, T. et al. (1995) Collagen metabolism in obesity: the effect of weight loss. International Journal of Obesity and Related Metabolic Disorders, 19, 659-663.
31. Sharma, S., Mells, J.E., Fu, P.P. et al. (2011) GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE, 6, e25269.
32. Gupta, N.A., Mells, J., Dunham, R.M. et al. (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 51, 1584-1592.
33. Ding, X., Saxena, N.K., Lin, S. et al. (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 43, 173-181.
34. Lee, J., Hong, S.W., Chae, S.W. et al. (2012) Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS ONE, 7, e31394.
35. Lee, J., Hong, S.W., Rhee, E.J. et al. (2012) GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes and Metabolism Journal, 36, 262-267.